Turkiye Klinikleri Cardiovascular Sciences

.: ORIGINAL RESEARCH
Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization
Hastanede Yatış Sırasında Ölen Sınırda/Düşük Ejeksiyon Fraksiyonlu Kalp Yetersizliği Hastalarında Klinik Özelliklerin ve Yaşam Süresinin Tek Merkezli Retrospektif Değerlendirilmesi
Ferhat DİNDAŞa, Okan Onur TURGUTa, Mehmet Birhan YILMAZa
aSivas Cumhuriyet University Faculty of Medicine, Department of Cardiology, Sivas, TURKEY
Turkiye Klinikleri J Cardiovasc Sci. 2020;32(2):59-67
doi: 10.5336/cardiosci.2020-75417
Article Language: EN
Full Text
ABSTRACT
 Objective: Today, despite medical developments the frequency of heart failure is increasing. The current guidelines have categorized patients with heart failure (HF) by their phenotypes to better explain them. In our study, we aimed to compare the basic clinical features, drug treatment and the life expectancy in HF phenotypes who died during hospitalization. Material and Methods: 100 consecutive patients who admitted with HF between 2011 and 2018 and died of cardiac cause during last hospitalization were evaluated. Patients with left ventricle ejection fraction (LVEF) 41-49% and N-terminal pro-B type natriuretic peptide (NT-proBNP) level >125 pg/mL were classified in the study as HFmrEF. Patients with EF% ≤40 NT-proBNP level >125 pg/mL were classified in the study as HFrEF. There were 50 patients from each HF group. Patients' demographic features, major laboratory parameters, drug treatments and life expectancy were evaluated in retrospective analysis. SPSS version 17.0 program was used for statistical analysis. p<0.05 was considered statistically significant. Results: The LVEF values of HfrEF and HFmrEF patients were 30% (15-38) and 45% (40-49), respectively. There was no significant difference between groups in drug treatment. The life expectancy values of the groups were 15 (1-61) months in the HFmrEF group and 11 (1-49) months in the HFrEF group (p=0.043). Conclusion: In our study, it was concluded that the demographic characteristics of HFrEF and HFmrEF patients were different. The life expectancy in HFmrEF group was longer than in HFrEF group.

Keywords: Heart failure; death; demography; cardiology service, hospital; life expectancy
ÖZET
 Amaç: Günümüzde, medikal gelişmelere rağmen kalp yetersizliği (KY) sıklığı artmaktadır. Mevcut kılavuzlar kalp yetersizliği hastalarını daha iyi açıklamak için fenotiplerine göre sınıflandırmıştır. Biz çalışmamızda, hastanede ölen KY fenotiplerinin temel klinik özelliklerini, ilaç tedavilerini ve yaşam sürelerini kıyaslamayı hedefledik. Gereç ve Yöntemler: 2011-2018 yılları arasında kalp yetersizliği ile başvuran ve son hastaneye yatışı sırasında kardiyak nedenden ölen 100 ardışık hasta değerlendirildi. Çalışmada EF% 41-49 ve N-terminal pro- B tipi natriüretik peptit (NT-proBNP) düzeyi >125 pg/mL olan hastalar SEF-KY olarak sınıflandırıldı. Çalışmada EF%≤40 ve NT-proBNP düzeyi >125 pg/mL olan hastalar DEF-KY olarak sınıflandırıldı. Her iki KY grubunda 50 hasta vardı. Retrospektif analizimizde hastaların demografik özellikleri, başlıca laboratuvar parametreleri, ilaç tedavileri ve tahmini yaşam süreleri değerlendirildi. İstatistiksel incelemede SPSS versiyon 17.0 programı kullanıldı. p<0,05 istatiksel olarak anlamlı kabul edildi. Bulgular: DEF-KY ve SEF-KY hastalarının EF değerleri sırasıyla %30 (15-38) ve %45 (40-49) idi. İlaç tedavilerinde gruplar arasında anlamlı bir fark yoktu. Grupların yaşam ürelerinin değerleri SEF-KY grubunda 15 (1-61) ay ve DEF-KY grubunda 11 (1-49) ay olarak saptandı (p=0.043). Sonuç: Çalışmamızda DEF-KY ve SEF-KY hastalarının demografik özelliklerinin farklı olduğu sonucuna varıldı. SEF-KY grubundaki yaşam süresi DEF-KY grubuna göre daha uzundu.

Anahtar Kelimeler: Kalp yetersizliği; ölüm; demografi; kardiyoloji servisi, hastane; yaşam beklentisi
REFERENCES:
  1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1-90.
  2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A-13A. [Crossref] 
  3. Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail. 2011;4(4):396-403. [Crossref]  [PubMed] 
  4. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108(8):977-82. [Crossref]  [PubMed] 
  5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709-17. [Crossref]  [PubMed] 
  6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al; American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.
  7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
  8. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19(12):1574-85. [Crossref]  [PubMed] 
  9. Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, et al; TIME-CHF Investigators. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the trial of intensified versus standard medical therapy in elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. 2017;19(12):1586-96. [Crossref]  [PubMed] 
  10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J Fail. 2016;18(8):891-975.
  11. Lam CSP, Solomon SD. Fussing over the middle child: heart failure with mid-range ejection fraction. Circulation. 2017;135(14):1279-80. [Crossref]  [PubMed] 
  12. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1597-605. [Crossref]  [PubMed]  [PMC] 
  13. MB Yılmaz, Çelik A, Çavuşoğlu Y, Bekar L, Onrat E, Eren M, et al. [Snapshot evaluation of heart failure in Turkey: baseline characteristics of SELFIE-TR]. Turk Kardiyol Dern Ars. 2019;47(3):198-206.
  14. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (REACH) study. J Am Coll Cardiol. 2002;39(1):60-9. [Crossref] 
  15. Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK, et al. [Heart failure prevalence and predictors in Turkey: HAPPY study]. Turk Kardiyol Dern Ars. 2012;40(4): 298-308. [Crossref]  [PubMed] 
  16. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46. [Crossref]  [PubMed]  [PMC] 
  17. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016;4(6):464-72. [Crossref]  [PubMed] 
  18. Coles AH, Tisminetzky M, Yarzebski J, Lessard D, Gore JM, Darling CE, et al. Magnitude of and prognostic factors associated with 1-year mortality after hospital discharge for acute decompensated heart failure based on ejection fraction findings. J Am Heart Assoc. 2015;4(12):e002303. [Crossref]  [PubMed]  [PMC] 
  19. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the medicare population. Am Heart J. 2014;168(5):721-30. [Crossref]  [PubMed] 
  20. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5(6):720-6. [Crossref]  [PubMed]  [PMC] 
  21. Nadruz Jr W, West E, Santos M, Skali H, Groarke JD, Forman DE, et al. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail. 2016;9(4):e002826. [Crossref]  [PubMed]  [PMC] 
  22. Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Fail. 2019;6(4):784-92. [Crossref]  [PubMed]  [PMC] 
  23. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study. Eur J Heart Fail. 2017;19(10):1258-69. [Crossref]  [PubMed] 
  24. Bloomfield GS, Barasa FA, Doll JA, Velazquez EJ. Heart failure in sub-Saharan Africa. Curr Cardiol Rev. 2013;9(2):157-73. [Crossref]  [PubMed]  [PMC] 
  25. Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2018;5(4):685-94. [Crossref]  [PubMed]  [PMC] 
  26. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75. [Crossref]  [PubMed] 
  27. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624-34. [Crossref]  [PubMed] 
  28. Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1606-14. [Crossref]  [PubMed] 
  29. Webb J, Draper J, Fovargue L, Sieniewicz B, Gould J, Claridge S, et al. Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group? Int J Cardiol Heart Vasc. 2018;21:1-6. [Crossref]  [PubMed]  [PMC] 
  30. Nielsen OW, Valeur N, Sajadieh A, Fabricius-Bjerre A, Carlsen CM, Kober L. Echocardiographic subtypes of heart failure in consecutive hospitalised patients with dyspnoea. Open Heart. 2019;6(1):e000928. [Crossref]  [PubMed]  [PMC] 
  31. Chen X, Xin Y, Hu W, Zhao Y, Zhang Z, Zhou Y. Quality of life and outcomes in heart failure patients with ejection fractions in different ranges. PLoS One. 2019;14(6):e0218983. [Crossref]  [PubMed]  [PMC] 
  32. Solomon SD, Anavekar N, Skali H, Mcmurray JJV, Swedberg K, Yusuf S, et al; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112(24):3728-44. [Crossref]  [PubMed] 
  33. Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A. Clinical characteristics and prognosis of patients admitted for heart failure: a 5-year retrospective study of African patients. Int J Cardiol. 2017;238:128-35. [Crossref]  [PubMed] 
  34. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-54. [Crossref]  [PubMed] 
  35. Lyu S, Yu L, Tan H, Liu S, Liu X, Guo X, et al. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China. BMC Cardiovasc Disord. 2019;19(1):209. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com